Ich stimme zu, dass diese Seite Cookies verwende. Weitere Informationen finden Sie unter unseren Datenschutzerklärungen .
X
Piasecka-Stryczynska, Karolina
15  Ergebnisse:
Personensuche X
?
1

Efficacy and safety results after >3.5 years of treatment w..:

Montalban, Xavier ; Piasecka-Stryczynska, Karolina ; Kuhle, Jens...
Multiple Sclerosis Journal.  30 (2024)  4-5 - p. 558-570 , 2024
Link: https://doi.org/10.1177/..
 
?
2

Update on Long-Term Efficacy and Safety of Evobrutinib, a B..:

Montalban, Xavier ; Wolinsky, Jerry S. ; Arnold, Douglas L....
Multiple Sclerosis and Related Disorders.  80 (2023)  - p. 105329 , 2023
Link: https://doi.org/10.1016/..
 
?
3

Efficacy and Safety of the Bruton's Tyrosine Kinase Inhibit..:

Montalban, Xavier ; Wolinsky, Jerry S. ; Arnold, Douglas L....
Neurology.  100 (2023)  17_supplement_2 - p. , 2023
Link: https://doi.org/10.1212/..
 
?
4

Safety and Efficacy of Evobrutinib, a Bruton's Tyrosine Kin..:

Montalban, Xavier ; Wolinsky, Jerry S. ; Arnold, Douglas L....
Neurology.  98 (2022)  18_supplement - p. , 2022
Link: https://doi.org/10.1212/..
 
?
5

Concentration of evobrutinib, a BTK inhibitor, in cerebrosp..:

Piasecka-Stryczynska, Karolina ; Rejdak, Konrad ; Dyroff, Martin...
Multiple Sclerosis and Related Disorders.  51 (2021)  - p. 103001 , 2021
Link: https://doi.org/10.1016/..
 
?
6

Safety of Evobrutinib in Patients With Relapsing Multiple S..:

Montalban, Xavier ; Arnold, Douglas L. ; Weber, Martin S....
Neurology.  96 (2021)  15_supplement - p. , 2021
Link: https://doi.org/10.1212/..
 
?
7

Taux de poussées chez les patients atteints de SEP rémitten..:

Montalban, Xavier ; Arnold, Douglas ; Weber, Martin S....
Revue Neurologique.  177 (2021)  - p. S123 , 2021
Link: https://doi.org/10.1016/..
 
?
8

Evobrutinib Efficacy is Maintained Over Two Years in an Ope..:

Montalban, Xavier ; Arnold, Douglas L. ; Weber, Martin S....
Neurology.  96 (2021)  15_supplement - p. , 2021
Link: https://doi.org/10.1212/..
 
?
9

Efficacy and Safety of the Bruton's Tyrosine Kinase Inhibit..:

Montalban, Xavier ; Arnold, Douglas L ; Weber, Martin S...
Multiple Sclerosis and Related Disorders.  37 (2020)  - p. 101603 , 2020
Link: https://doi.org/10.1016/..
 
?
10

Efficacy and Safety of the Bruton's Tyrosine Kinase Inhibit..:

Montalban, Xavier ; Arnold, Douglas L. ; Weber, Martin S....
Neurology.  92 (2019)  15_supplement - p. , 2019
Link: https://doi.org/10.1212/..
 
?
11

"Positive Regulation of RNA Metabolic Process" Ontology Gro..:

Celichowski, Piotr ; Nawrocki, Mariusz J. ; Dyszkiewicz-Konwińska, Marta...
BioMed Research International.  2018 (2018)  - p. 1-10 , 2018
Link: https://doi.org/10.1155/..
 
?
12

Efficacy and Safety of the Bruton's Tyrosine Kinase Inhibit..:

Montalban, Xavier ; Wolinsky, Jerry S ; Arnold, Douglas L...
https://resolver.sub.uni-goettingen.de/purl?gro-2/138645.  , 2023
Link: https://resolver.sub.uni..
 
?
13

Placebo-controlled trial of an oral BTK inhibitor in multip..:

Montalban Gairín, Xavier ; Douglas, Arnold L ; Martin, Weber S...
New England Journal of Medicine;380(25).  , 2019
Link: https://hdl.handle.net/1..
 
?
14

Placebo-Controlled Trial of an Oral BTK Inhibitor in Multip..:

Montalban, Xavier ; Arnold, Douglas L ; Weber, Martin S...
https://resolver.sub.uni-goettingen.de/purl?gro-2/134326.  , 2019
Link: https://resolver.sub.uni..
 
?
15

"Positive Regulation of RNA Metabolic Process" Ontology Gro..:

Piotr Celichowski ; Mariusz J. Nawrocki ; Marta Dyszkiewicz-Konwińska...
http://dx.doi.org/10.1155/2018/2863068.  , 2018
Link: https://doi.org/10.1155/..
 
1-15